IntelliCell BioSciences Appoints Dr. Sigmund Norr to Its Board of Advisors

NEW YORK, NY--(Marketwire - October 19, 2011) - IntelliCell BioSciences, Inc. (OTCQB: SVFC) (PINKSHEETS: SVFC) (“IntelliCell” or the “Company”), a leader in regenerative medicine and the manufacturing of stromal vascular fraction (SVF) containing adipose derived adult stem cells, announced today it has appointed pediatrician, Dr. Sigmund Norr to its Board of Advisors. Dr. Norr, of the Cleveland Clinic, joins ten other prominent doctors on the Company’s Board of Advisors.

Sigmund Carl Norr, Ph.D., M.D., practices general pediatrics and serves as Section Head of Pediatrics at the Willoughby Hills Family Health Center. Prior to joining the Cleveland Clinic, Dr. Norr was Medical Director and staff physician at MEDGroup in Fairlawn, Ohio. Preceding that, Dr. Norr served in a number of roles with Ohio Permanente Medical Group, including Medical Director of the Alcohol Chemical Dependency Program, and Chief of the Department of Pediatric and Adolescent Medicine.

He is board-certified in pediatrics and addiction medicine. Dr. Norr received his undergraduate degree in biology from the University of Pittsburgh. He completed a doctorate in developmental cell biology at Case Western Reserve University and earned his medical degree from the University of Miami. He completed an internship and residency in pediatric medicine at Rainbow Babies and Children’s Hospital in Cleveland, Ohio.

Dr. Norr is a member of the American Academy of Pediatrics. His specialty interests include ambulatory pediatrics and adolescent medicine, ADHD, asthma, and adolescent chemical dependency. He has published and spoken on the topics of neurobiology and cell biology.

“We welcome Dr. Norr aboard and look forward to what we’re sure will be a substantive contribution to IntelliCell given his extensive knowledge of cell biology and pediatric medicine,” stated IntelliCell Chairman and CEO, Dr. Steven Victor.

The use of autologous adipose (fat) stem cells for a growing variety of indications is a new and exciting frontier in medicine. In the aesthetic world the use of autologous adipose stem cells has become widely accepted in Europe and Asia. Since the middle of 2009 when the US FDA published its laws on autologous stem cells the field has expanded rapidly. Currently, doctors, companies and researchers are studying the use of these adipose stem cells for aesthetics; the treatment of arthritis; and numerous orthopedic injuries such as knees, elbows, back, and shoulders; wound healing; congestive heart failure; gum regeneration and other ailments.

About IntelliCell Biosciences, Inc.

IntelliCell is a pioneering regenerative medicine company focused on the expanding regenerative medical markets using stromal vascular fraction derived from adult adipose tissue. IntelliCell intends to initially focus on setting up tissue processing centers throughout the United States with managing partners. The centers will receive and employ the IntelliCell™ process to the adipose stromal vascular fraction harvested by physicians in their own offices, and then return the IntelliCells™ to the physicians the same day labeled “autologous homologous.” IntelliCell has already established processing centers in Baton Rouge, New York City, Philadelphia, Dallas/Ft. Worth, Denver, Houston, New Orleans, Orlando, and West Palm Beach. In the future, IntelliCell intends to pursue expansion to secondary markets and beyond the U.S. through a combination of company-owned and licensed clinical facilities. For additional information, visit http://www.intellicellbiosciences.com or call 212 249 3050.

Forward-Looking Statements
Certain statements set forth in this press release constitute “forward-looking statements.” Forward-looking statements include, without limitation, any statement that may predict, forecast, indicate, or imply future results, performance or achievements, and may contain the words “estimate,” “project,” “intend,” “forecast,” “anticipate,” “plan,” “planning,” “expect,” “believe,” “will likely,” “should,” “could,” “would,” “may” or words or expressions of similar meaning. Such statements are not guarantees of future performance and are subject to risks and uncertainties that could cause the company’s actual results and financial position to differ materially from those included within the forward-looking statements. Forward-looking statements involve risks and uncertainties, including those relating to the Company’s ability to grow its business. Actual results may differ materially from the results predicted and reported results should not be considered as an indication of future performance. The potential risks and uncertainties include, among others, the Company’s limited operating history, the limited financial resources, domestic or global economic conditions, activities of competitors and the presence of new or additional competition, and changes in Federal or State laws. More information about the potential factors that could affect the Company’s business and financial results is included in the Company’s filings, available via the United States Securities and Exchange Commission.

Digg this Bookmark with del.icio.us Add to Newsvine

Technorati: stem cells regenerative medicine medical advisory board pediatrics stromal vascular fraction